Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDe-2 open-label extension of oral PHA-022121 for acute hereditary angioedema attacks
MOH_2022-11-29_012206Phase 3Recruiting
- Sponsor
- Pharvaris
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of deucrictibant in hereditary angioedema (HAE) (2 arms), sponsored by Pharvaris. Started Oct 2022; status: recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2022-11-29_012206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-29_012206.